Skip to main content

Telangiectasia clinical trials at UCSD

1 in progress, 0 open to eligible people

Showing trials for
  • Pomalidomide for the Treatment of Bleeding in HHT

    Sorry, in progress, not accepting new patients

    This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or blood transfusions. A total of 159 patients will be randomized 2:1 to treatment with oral pomalidomide or matching placebo for 24 weeks. Mean change from baseline to 24 weeks in the Epistaxis Severity Score (ESS) will be compared between treatment groups to determine pomalidomide efficacy.

    San Diego, California and other locations

Last updated: